CN108558899B - California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof - Google Patents

California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof Download PDF

Info

Publication number
CN108558899B
CN108558899B CN201810469176.XA CN201810469176A CN108558899B CN 108558899 B CN108558899 B CN 108558899B CN 201810469176 A CN201810469176 A CN 201810469176A CN 108558899 B CN108558899 B CN 108558899B
Authority
CN
China
Prior art keywords
formula
compound
reaction
further preferred
carixanthomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201810469176.XA
Other languages
Chinese (zh)
Other versions
CN108558899A (en
Inventor
申艳芳
代义华
马飞霞
高栓虎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China Normal University
Original Assignee
East China Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China Normal University filed Critical East China Normal University
Priority to CN201810469176.XA priority Critical patent/CN108558899B/en
Publication of CN108558899A publication Critical patent/CN108558899A/en
Application granted granted Critical
Publication of CN108558899B publication Critical patent/CN108558899B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a calicheamicin A glycosyl ligand, an intermediate and a preparation method thereof, wherein the calicheamicin A glycosyl ligand has a chemical structure shown in a formula 1:
Figure DDA0001662678100000011
the preparation method of the carixanthomycin A glycosyl ligand comprises the following steps (2) or steps (1) to (2) in a synthetic route:
Figure DDA0001662678100000012
the invention also discloses a carixanthomycin A glycosyl ligand intermediate which has the chemical structures shown in formulas 2, 4, 5 and 7 respectively:
Figure DDA0001662678100000013

Description

California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof
Technical Field
The invention relates to a carixanthomycin A glycosyl ligand, an intermediate and a preparation method thereof, belonging to the technical field of chemical drug synthesis.
Background
The kallidamycin A is a polycyclic xanthone natural product, is obtained by introducing an amplification gene sequence of a polyphenol natural product into Streptomyces albus by a Brady task group and separating the product from a culture solution of the Streptomyces albus, has strong inhibitory activity on human colon cancer cells, and has an IC50 value as low as 0.43nM (Hahk-Soo K.; Brady, S.; J.Am.chem.S.2014,136,18111-18119.), and has the following chemical structure:
Figure BDA0001662678090000011
as a novel polycyclic xanthone natural product, the kalifamycin A has a wide application prospect, but no reports related to chemical synthesis of the kalifamycin A exist at present due to the high oxidation state and complex six-ring structure of the kalifamycin A.
The inventor researches and discovers that if the carixanthomycin A glycosyl ligand is synthesized firstly
Figure BDA0001662678090000012
Only one-step glycosylation is needed to synthesize the calicheamicin A, but no report related to the calicheamicin A glycosyl ligand exists at present, and no report related to the chemical synthesis of the calicheamicin A glycosyl ligand exists.
Disclosure of Invention
In view of the above problems in the prior art, the present invention aims to provide a carixanthomycin a glycosyl ligand, an intermediate thereof and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a calicheamicin A glycosyl ligand has a chemical structure shown in formula 1:
Figure BDA0001662678090000021
a method for preparing a calicheamicin a glycosyl ligand represented by formula 1, comprising step (2) or steps (1) to (2) in the following synthetic scheme:
Figure BDA0001662678090000022
preferably, the step (1) is to selectively remove the carbonyl ortho-methyl and benzyl from the compound of formula 2 under the action of lewis acid to obtain the compound of formula 3.
In a further preferred embodiment, in the step (1), the lewis acid is selected from any one of boron trichloride, boron trifluoride and aluminum trichloride, and preferably boron trichloride.
As a further preferable mode, in the step (1), the reaction solvent is C1～C10And halogenated hydrocarbon solvents (for example, dichloromethane, trichloromethane, carbon tetrachloride, 1, 2-dichloroethane, etc.).
As a further preferred embodiment, in step (1), a compound of formula 2: the molar ratio of Lewis acid is 1: (3-8).
Preferably, the step (2) is to remove the methyl group at the para-position of the phenolic hydroxyl group in the compound of formula 3 selectively under the action of a dealkylation reagent to obtain the compound of formula 1 from the compound of formula 3.
As a further preferred embodiment, in step (2), the dealkylating agent is iodobenzene bistrifluoroacetate (also known as [ bis (trifluoroacetoxy) iodo ] benzene, CAS # 2712-78-9).
As a further preferred embodiment, in step (2), a compound of formula 3: the molar ratio of dealkylating agent is 1: (4-8).
As a further preferable mode, in the step (2), the reaction solvent is C1～C10A mixed solvent of a nitrile solvent (e.g., acetonitrile) or a ketone solvent (e.g., acetonitrile) and water.
A calicheamicin A glycosyl ligand intermediate has a chemical structure shown in formula 2:
Figure BDA0001662678090000031
a method for preparing a carixanthomycin A glycosyl ligand intermediate shown in a formula 2 comprises the following steps of firstly carrying out oxidation reaction on a compound shown in a formula 4 until aldehyde groups in the compound shown in the formula 4 are oxidized into carboxyl groups to obtain an oxidation product, and carrying out intramolecular Friedel-crafts acylation reaction on the obtained oxidation product to obtain a compound shown in the formula 2, wherein the chemical reaction formula is as follows:
Figure BDA0001662678090000032
as a preferred embodiment, the preparation of the compound of formula 2 is performed as follows: dissolving the compound shown in the formula 4 in a solvent A, and performing oxidation reaction with hydrogen peroxide and sodium chlorite under a neutral condition until aldehyde groups in the compound shown in the formula 4 are oxidized into carboxyl groups to obtain an oxidation product; the obtained oxidation product is directly dissolved in a solvent B, reacts with oxalyl chloride in the presence of a catalyst to obtain an acyl chloride intermediate, and then the obtained acyl chloride intermediate is subjected to intramolecular Friedel-crafts acylation reaction in a fluorinated solvent to obtain the compound shown in the formula 2.
As a further preferable mode, the solvent A is C1～C10A mixed solvent of water and a nitrile solvent (e.g., acetonitrile), the nitrile solvent: the volume ratio of water is (3-10): 1.
as a further preferred embodiment, the compound of formula 4: hydrogen peroxide: sodium chlorite: in a molar ratio of 1: (1-3): (1-3).
In a more preferred embodiment, the solvent B is a reaction solvent C1～C10And halogenated hydrocarbon solvents (for example, dichloromethane, trichloromethane, carbon tetrachloride, 1, 2-dichloroethane, etc.).
In a further preferred embodiment, the catalyst is N, N-dimethylformamide.
As a further preferred embodiment, the compound of formula 4: the molar ratio of the catalyst is 1: (2-4).
In a further preferred embodiment, the fluorinated solvent is hexafluoroisopropanol.
A calicheamicin A glycosyl ligand intermediate has a chemical structure shown in formula 4:
Figure BDA0001662678090000041
a method for preparing a carixanthomycin A glycosyl ligand intermediate shown in a formula 4 is to obtain a compound shown in the formula 4 by an aromatic nucleophilic substitution reaction of a compound shown in a formula 5 and a compound shown in a formula 6, wherein the chemical reaction formula is as follows:
Figure BDA0001662678090000042
as a preferred embodiment, the preparation of the compound of formula 4 is performed as follows: and (3) carrying out an aromatic nucleophilic substitution reaction on the compound of the formula 5 and the compound of the formula 6 at 110-130 ℃ in the presence of alkali to obtain the compound of the formula 4.
In a further preferred embodiment, the reaction solvent is N, N-dimethylformamide.
More preferably, the base is an inorganic base selected from any one of sodium carbonate, potassium carbonate, calcium carbonate and cesium carbonate.
Preferably, the compound of formula 5: alkali: the molar ratio of the compounds of formula 6 is 1: (1-2): (1-2).
A calicheamicin A glycosyl ligand intermediate has a chemical structure shown in formula 5:
Figure BDA0001662678090000043
a method for preparing a carixanthomycin A glycosyl ligand intermediate shown in formula 5 comprises the following steps of (c), (c) - (c) or (c) - (c):
Figure BDA0001662678090000051
preferably, the compound of formula 7 is subjected to a reduction reaction with hydrogen in the presence of a catalyst to obtain the compound of formula 8.
In a further preferred embodiment, in step (i), the catalyst is a palladium catalyst (e.g., palladium/barium sulfate).
As a further preferable mode, in the step (i), the reaction solvent used is C1～C10Ether solvents (e.g., tetrahydrofuran, dioxane, etc.).
As a further preferred embodiment, in step (i), the compound of formula 7: the molar ratio of the catalyst is 10: 1-10: 3.
Preferably, the step (II) is to perform an iodination reaction on the compound of the formula 8 with an iodination reagent in the presence of a base to obtain the compound of the formula 9.
In a further preferred embodiment, in the step (ii), the base used is an inorganic base selected from one or a mixture of two or more of sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, potassium bicarbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide and barium hydroxide.
As a further preferred embodiment, in step (II), the iodinating agent is benzyltrimethylammoniumdichloroiodate (CAS # 114971-52-7).
As a further preferable scheme, in the step (II), C1～C10Or a halogenated hydrocarbon solvent (e.g., dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, etc.), or a mixture thereof.
In the second step, the reaction temperature of iodination is 50-60 ℃.
As a further preferred embodiment, in step (ii), the compound of formula 8: iodination reagent: the molar ratio of the alkali is 1: (1-3): (5-12).
Preferably, the step (c) is to perform intramolecular radical cyclization reaction on the compound of the formula 9 in the presence of alkali under ultraviolet irradiation to obtain the compound of the formula 5.
In a further preferred embodiment, in step (c), the base used is an organic base selected from any one or a mixture of two or more of diisopropylamine, triethylamine, diisopropylethylamine, pyridine, 2, 6-dimethylpyridine, 2-hydroxypyridine, piperidine, N-methylpiperidine, morpholine and N-methylmorpholine.
As a further preferable scheme, in the step (C), the reaction solvent used is C1～C10And (3) nitrile solvents (e.g., acetonitrile, etc.).
As a further preferred embodiment, in step (iii), the compound of formula 9: the molar ratio of the alkali is 1: (5-15).
A calicheamicin A glycosyl ligand intermediate has a chemical structure shown in formula 7:
Figure BDA0001662678090000061
a method for preparing a carixanthomycin A glycosyl ligand intermediate shown in a formula 7 is to obtain a compound shown in the formula 7 by a coupling reaction of a compound shown in a formula 10 and a compound shown in a formula 11 through sonogashira, wherein the chemical reaction formula is as follows:
Figure BDA0001662678090000062
as a preferred embodiment, the preparation of the compound of formula 7 is performed as follows: the compound shown in the formula 10 and the compound shown in the formula 11 are subjected to sonogashira coupling reaction at 90-100 ℃ in a mixed solvent of an organic solvent and an organic base under the catalysis of a palladium catalyst and cuprous iodide to obtain the compound shown in the formula 7.
More preferably, the volume ratio of the organic solvent to the organic base in the mixed solvent is (3-10): 1.
In a further preferred embodiment, the organic solvent is N, N-dimethylformamide.
In a further preferred embodiment, the organic base is selected from any one or a mixture of two or more of diisopropylamine, triethylamine, diisopropylethylamine, pyridine, 2-hydroxypyridine, piperidine, N-methylpiperidine, morpholine and N-methylmorpholine.
As a further preferred embodiment, the palladium catalyst is bis-triphenylphosphine palladium dichloride or tetrakis-triphenylphosphine palladium.
As a preferred embodiment, compounds of formula 10: the molar ratio of the compound of formula 11 is 1: 1-1: 2.
As a preferred scheme, the preparation of formula 10 comprises the steps h or g to h or f to g to h or e to f to g to h or d to e to f to g to h or c to d to e to f to g to h or b to c to d to e to f to g to h or a step a to b to c to d to e to f to g to h in the following synthetic routes:
Figure BDA0001662678090000071
as a further preferred embodiment, said step a is to obtain the compound of formula 10-2 by reacting the compound of formula 10-1 with allyl halide in the presence of a phase transfer catalyst and a base.
As a further preferred embodiment, in step a, the phase transfer catalyst is a quaternary ammonium salt (e.g., tetrabutylammonium iodide).
In a further preferred embodiment, in step a, the base is an inorganic base selected from any one or a mixture of two or more of sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate and potassium bicarbonate.
As a further preferred embodiment, in step a, the allyl halide is allyl bromide.
In a further preferred embodiment, in step a, the reaction solvent is a halogenated hydrocarbon solvent (e.g., dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, etc.) or a ketone solvent (e.g., acetone) having a carbon number of from C1 to C10; the reaction temperature is 40-60 ℃.
As a still further preferred embodiment, in step a, a compound of formula 10-1: alkali: the molar ratio of allyl halides is 1: (1-2): (1-1.5).
As a further preferable scheme, the compound of the formula 10-3 is obtained by reacting the compound of the formula 10-2 with 1, 1-dichloromethyl ether in the presence of Lewis acid.
As a further preferred embodiment, in step b, the Lewis acid is titanium tetrachloride.
As a still further preferred embodiment, in step b, the compound of formula 10-2: lewis acid: the mol ratio of 1, 1-dichloromethyl ether is 5: (8-10): (5-8).
In a more preferred embodiment, the reaction solvent in step b is a halogenated hydrocarbon solvent of C1-C10 (e.g., dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, etc.).
As a further preferred scheme, the step c is to perform an oxidation reaction on the compound of the formula 10-3 with hydrogen peroxide and sodium chlorite under a neutral condition until aldehyde groups in the compound of the formula 10-3 are oxidized into carboxyl groups to obtain the compound of the formula 10-4.
As a further preferred embodiment, in step C, the reaction solvent is C1～C10A mixed solvent of water and a nitrile solvent (e.g., acetonitrile), the nitrile solvent: the volume ratio of water is (3-10): 1.
As a still further preferred embodiment, in step c, a compound of formula 10-3: hydrogen peroxide: sodium chlorite: in a molar ratio of 1: (1-3): (1-3).
As a further preferred embodiment, said step d is to react the compound of formula 10-4 with a methylating agent in the presence of a base to obtain the compound of formula 10-5.
As a further preferred embodiment, in step d, the methylating agent is dimethyl sulphate.
In a further preferred embodiment, in step d, the base is an inorganic base selected from any one or a mixture of two or more of sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate and potassium bicarbonate.
In a further preferred embodiment, in step d, the reaction solvent is N, N-dimethylformamide.
As a still further preferred embodiment, in step d, the compound of formula 10-4: alkali: the molar ratio of the methylating agents is 1: (1-3): (1-2).
In a further preferable scheme, the compound of the formula 10-6 is obtained by performing a claisen rearrangement reaction on the compound of the formula 10-5 in an amine solvent at 180-220 ℃.
In a further preferred embodiment, in step e, the amine solvent is N-methylpyrrolidone.
As a further preferred embodiment, said step f is to react the compound of formula 10-6 with a methylating agent in the presence of a base to obtain the compound of formula 10-7.
As a further preferred embodiment, in step f, the methylating agent is dimethyl sulfate or methyl iodide.
In a further preferred embodiment, in step f, the base is an inorganic base selected from any one or a mixture of two or more of sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, potassium bicarbonate and sodium hydride.
In a further preferred embodiment, in step f, the reaction solvent is N, N-dimethylformamide.
As a still further preferred embodiment, in step f, the compound of formula 10-6: alkali: the molar ratio of the methylating agents is 1: (1-3): (1-2).
As a further preferable scheme, the step g is that the compound of the formula 10-7 is subjected to a Wacker oxidation reaction with oxygen under the catalysis of palladium chloride and cuprous chloride to obtain the compound of the formula 10-8.
As a further preferred embodiment, in step g, the reaction solvent is C1～C10A mixed solvent of the ether solvent (e.g., dioxane, tetrahydrofuran, etc.) and water, ether solvent: the volume ratio of water is (3-10): 1.
As a still further preferred embodiment, in step g, the compound of formula 10-7: palladium chloride: the mol ratio of cuprous chloride is 10: (0.5-1.5): (8-15).
As a further preferable scheme, the step h is to perform hydroboration reduction reaction on the compound of the formula 10-8 and borohydride to obtain the compound of the formula 10.
As a further preferred embodiment, in step h, the borohydride is sodium borohydride.
As a still further preferred embodiment, in step h, the compound of formula 10-8: the molar ratio of borohydride is 1: (2-3).
Preferably, the preparation of the compound of formula 11 comprises steps E or steps D to E or steps C to D to E or steps B to C to D to E or steps A to B to C to D to E in the following synthetic routes:
Figure BDA0001662678090000091
as a further preferred scheme, the step A is to react the compound of the formula 11-1 with benzyl halide in the presence of alkali to obtain the compound of the formula 11-2.
In a further preferred embodiment, in step a, the base used is an inorganic base selected from any one or a mixture of two or more of sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate and potassium bicarbonate.
As a further preferred embodiment, in step A, the benzyl halide is benzyl chloride or benzyl bromide.
In a further preferred embodiment, in step A, the reaction solvent is N, N-dimethylformamide.
As a still further preferred embodiment, in step A, a compound of formula 11-1: alkali: the molar ratio of the halogenated benzyl is 1: (1-3): (1-2).
As a further preferred scheme, the step B is that the compound of the formula 11-2 is firstly reacted with the peroxy compound, and the obtained product intermediate is hydrolyzed in alkaline aqueous solution or acidic alcohol solution to obtain the compound of the formula 11-3.
In a further preferred embodiment, in step B, the peroxy compound is m-chloroperoxybenzoic acid.
More preferably, in the step B, when the compound of formula 11-2 is reacted with the peroxy compound, the reaction solvent is a halogenated hydrocarbon solvent of C1-C10 (e.g., dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane), and the reaction temperature is 40-60 ℃.
In a further preferred embodiment, in step B, the alkaline aqueous solution is an aqueous sodium hydroxide solution, and the acidic alcoholic solution is an alcoholic solution of hydrochloric acid.
As a still further preferred embodiment, in step B, a compound of formula 11-2: the molar ratio of the peroxy compound is 1: 1-2: 3.
In a further preferable embodiment, the step C is to perform the sonogashira coupling reaction of the compound of formula 11-3 in a mixed solvent of an organic solvent and an organic base and with triisopropylsilyl acetylene at 100-120 ℃ under the catalysis of a palladium catalyst and cuprous iodide to obtain the compound of formula 11-4.
In a further preferable embodiment, in the step C, the volume ratio of the organic solvent to the organic base in the mixed solvent is (3-10): 1.
In a further preferred embodiment, in step C, the organic solvent is toluene.
In a further preferred embodiment, in step C, the organic base is selected from any one or a mixture of two or more of diisopropylamine, triethylamine, diisopropylethylamine, pyridine, 2-hydroxypyridine, piperidine, N-methylpiperidine, morpholine and N-methylmorpholine.
As a still further preferred embodiment, in step C, the palladium catalyst is bis triphenylphosphine palladium dichloride.
As a still further preferred embodiment, in step C, a compound of formula 11-3: the molar ratio of triisopropyl silyl acetylene is 1: 1-1: 2.
As a further preferable mode, the step D is to remove the triisopropylsilyl group on the alkynyl group from the compound of the formula 11-4 under the action of a fluorine reagent to obtain the compound of the formula 11-5.
In a further preferred embodiment, in step D, the fluorine reagent is tetrabutylammonium fluoride or pyridine hydrofluoric acid.
As a further preferred embodiment, in step D, the reaction solvent is C1～C10Ether solvents (e.g., tetrahydrofuran, dioxane, etc.).
As a still further preferred embodiment, in step D, a compound of formula 11-4: the molar ratio of the fluorine reagent is 1: 1-1: 2.
As a further preferable scheme, the step E is to react the compound of the formula 11-5 with triisopropylchlorosilane under the action of alkali and a catalyst to obtain the compound of the formula 11.
In a more preferred embodiment, the reaction solvent in step E is a halogenated hydrocarbon solvent of C1-C10 (e.g., dichloromethane, chloroform, carbon tetrachloride, 1, 2-dichloroethane, etc.).
As a further preferred embodiment, in step E, the catalyst is DMAP.
In a further preferred embodiment, in step E, the base is an organic base, and the organic base is any one of diisopropylamine, triethylamine and diisopropylethylamine.
As a still further preferred embodiment, in step E, a compound of formula 11-5: catalyst: alkali: the molar ratio of triisopropyl chlorosilane is 10: (0.5-1.5): (10-20): (10-15).
Compared with the prior art, the invention has the following remarkable beneficial effects:
the invention realizes the chemical synthesis of the carixanthomycin A glycosyl ligand for the first time, the prepared carixanthomycin A glycosyl ligand can be used for preparing the carixanthomycin A through simple glycosylation reaction, and the preparation method has strong practical value for realizing the chemical synthesis of the carixanthomycin A, has the advantages of simple operation, safety, no pollution, no special requirement on equipment, low production cost and the like, and has significant progress compared with the prior art; in addition, the intermediate products such as the compounds shown in the formulas 2, 4, 5 and 7 generated in the process of preparing the carixanthomycin A glycosyl ligand have more modifiable sites, and provide a new chemical synthesis direction for derivatives of the carixanthomycin A or other natural products with similar structures.
Detailed Description
The technical scheme of the invention is further detailed and completely explained by combining the embodiment.
Example 1: preparation of Compounds of formula 10
Step a: preparing a compound of formula 10-2:
Figure BDA0001662678090000111
the compound of formula 10-1 (10.0g,49.2mmol) was dissolved in acetone (120ml), potassium carbonate (10.2g,73.9mmol) and tetrabutylammonium fluoride (182mg,0.49mmol) were added, the mixture was stirred and mixed uniformly, allyl bromide (5.1ml,59.1mmol) was added, the reaction was terminated at 55 ℃ for 12 hours, the reaction mixture was cooled to room temperature, filtered through celite, concentrated, and the residue was separated by column chromatography (5% ethyl acetate/petroleum ether) to give the compound of formula 10-2 (11.77g, yield 98%) and Rf ═ 0.54 (10% ethyl acetate/petroleum ether).
Through the test:1H NMR(500MHz,Chloroform-d)δ7.14(d,J＝2.9Hz,1H),6.85(d,J＝8.9Hz,1H),6.80(d,J＝8.9Hz,1H),6.07(m,1H),5.48(dq,J＝17.2,1.6Hz,1H),5.31(d,J＝10.6Hz,1H),4.55(d,J＝3.7Hz,2H),3.76(s,3H)；
13C NMR(125MHz,CDCl3)δ154.3,149.3,133.1,118.9,117.6,115.1,113.6,112.2,70.7,55.9；
HRMS(EI):m/z calcd for[M]+:241.9942,found 241.9943。
step b: preparing a compound of formula 10-3:
Figure BDA0001662678090000121
the compound of formula 10-2 (12.10g,49.8mmol) was added to a dry dichloromethane solution (200ml) under nitrogen, adding 1, 1-dichloromethyl ether (8.1ml,89.6mmol) at 0 ℃, stirring and mixing uniformly, slowly dropwise adding a dichloromethane solution of titanium tetrachloride (1M dichloromethane, 59.7ml,59.7mmol), after dropwise adding, preserving heat and reacting for 2 hours, after the reaction was completed, the reaction solution was poured into an ice saturated sodium bicarbonate solution (200ml), stirred, separated, the aqueous phase was extracted 3 times with dichloromethane (80ml), the organic phases were combined, washed 1 time with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, the residue was separated by column chromatography (3-7% ethyl acetate/petroleum ether), to give a compound of formula 10-3 (6.09g, 45% yield), Rf ═ 0.56 (10% ethyl acetate/petroleum ether).
Through the test:1H NMR(500MHz,Chloroform-d)δ10.40(s,1H),7.35(s,1H),7.27(s,1H),6.11-6.03(m,1H),5.50(dd,J＝17.2,1.7Hz,1H),5.33(dd,J＝10.5,1.5Hz,1H),4.62(d,J＝5.1Hz,2H),3.92(s,3H)；
13C NMR(125MHz,CDCl3)δ188.7,156.3,149.4,132.3,124.1,121.0,118.1,117.6,111.4,70.3,56.4；
HRMS(EI):m/z calcd for[M]+:269.9892,found 269.9893。
step c: preparing a compound of formula 10-4:
Figure BDA0001662678090000122
adding a compound of a formula 10-3 (8.09g,29.80mmol) into a mixed solvent of acetonitrile (100ml) and water (20ml), uniformly stirring, then adding sodium dihydrogen phosphate dihydrate (930mg,5.96mmol), hydrogen peroxide (5.10ml, 30% v/v,44.70mmol), sodium chlorite (3.77g, dissolved in 20ml of water, 41.70mmol) at 0 ℃, keeping the temperature for reaction for 3 hours, then moving to room temperature for further reaction for 3 hours, finishing the reaction, quenching the reaction by using saturated sodium thiosulfate (10ml), decompressing and concentrating to remove excessive acetonitrile, adjusting the pH value of a residue to be about 4, extracting by using ethyl acetate for 3 times, combining organic phases, drying the organic phases by using anhydrous sodium sulfate, and concentrating to obtain a compound of a formula 10-4, wherein the obtained compound of the formula 10-4 is directly used for the next reaction without further purification.
Step d: preparing a compound of formula 10-5:
Figure BDA0001662678090000131
directly dissolving the compound of formula 10-4 obtained in step c in N, N-dimethylformamide (50ml), adding potassium carbonate (6.60g,47.9mmol) and dimethyl sulfate (3.40ml,35.1mmol), reacting at room temperature for 10 hours, terminating the reaction, quenching the reaction with saturated ammonium chloride solution (20ml), extracting with ethyl acetate (60ml) 3 times, combining the organic phases, washing the organic phases with water 3 times, washing with saturated sodium chloride solution 1 time, drying, filtering, concentrating, and separating the residue with column chromatography (6-8% ethyl acetate/petroleum ether) to obtain the compound of formula 10-5 (7.84g, total yield in steps c and d is 81%), and Rf is 0.66 (20% ethyl acetate/petroleum ether).
Through the test:1H NMR(400MHz,Chloroform-d)δ7.38(s,1H),7.20(s,1H),6.11–6.00(m,1H),5.47(d,J＝17.2Hz,1H),5.31(d,J＝11.5Hz,1H),4.58(d,J＝5.1Hz,2H),3.89(s,3H),3.87(s,3H)；
HRMS(EI):m/z calcd for[M]+:299.9997,found:300.0001。
step e: preparing a compound of formula 10-6:
Figure BDA0001662678090000132
dissolving the compound of formula 10-5 (2.56g,8.50mmol) in dry N-methylpyrrolidone (20ml), reacting at 200 ℃ for 2 hours under nitrogen protection, cooling the reaction solution to room temperature, adding saturated ammonium chloride solution (10ml), quenching the reaction, extracting with ethyl acetate (40ml) for 3 times, combining organic phases, washing the organic phases with distilled water and saturated saline water in sequence, drying with anhydrous sodium sulfate, filtering, concentrating, and separating the residue with column chromatography (5% ethyl acetate/petroleum ether) to obtain the compound of formula 10-6 (2.16g, 83% yield), Rf ═ 0.68 (20% ethyl acetate/petroleum ether).
Through the test:1H NMR(500MHz,Chloroform-d)δ6.96(s,1H),5.97-5.93(m,1H),5.34(s,1H),5.12–5.03(m,2H),3.91(s,3H),3.79(s,3H),3.41(d,J＝6.4Hz,2H)；
13C NMR(125MHz,CDCl3)δ167.4,150.2,144.7,134.9,125.7,124.8,116.2,113.1,111.3,56.6,52.3,32.8；
MS(EI):300(M+,71),302(71),285(23),269(100)。
step f: preparing a compound of formula 10-7:
Figure BDA0001662678090000141
the compound of formula 10-6 (6.0g,19.0mmol,1.0equiv.) was dissolved in 30ml of DMF, potassium carbonate (4.13mg,29.9mmol,1.5equiv.) and Me2SO4(2.1ml,21.9mmol,1.1equiv.) were added, reaction was carried out at room temperature for 6 hours, the reaction was terminated, 5ml of saturated NH was added4Quenching the reaction with aqueous Cl, extracting with ethyl acetate, combining the organic phases, washing the organic phases with saturated brine, drying over anhydrous sodium sulfate, filtering, concentrating, and subjecting the residue to column chromatography (10% ethyl acetate)Ester/petroleum ether) to give a compound of formula 10-7 (5.07g, 81% yield), Rf ═ 0.55 (15% ethyl acetate/petroleum ether).
Through the test:1H NMR(500MHz,Chloroform-d)δ6.97(s,1H),5.89-5.79(m,1H),5.02–4.93(m,2H),3.81(s,3H),3.73(s,3H),3.72(s,3H),3.39(dt,J＝6.4,1.7Hz,2H)ppm；
13C NMR(125MHz,CDCl3)δ167.1,152.8,149.2,135.6,133.1,124.3,118.9,116.2,114.4,61.3,56.3,52.1,32.3；
MS(EI):314(M+)。
step g: preparing a compound of formula 10-8:
Figure BDA0001662678090000142
dissolving the compound of formula 10-7 (4.96g,15.70mmol) in a mixed solvent of 1, 4-dioxane (70ml) and water (10ml), stirring well, adding palladium chloride (140mg,0.78mmol) and cuprous chloride (1.69g,18.8mmol), introducing oxygen, reacting at room temperature under oxygen atmosphere for 8 hours, ending the reaction, filtering the reaction solution with celite, extracting with ethyl acetate (40ml) three times, combining the organic phases, washing the organic phases with distilled water and saturated brine each once, drying, filtering, concentrating, separating the residue with column chromatography (5-15% ethyl acetate/petroleum ether) to obtain the compound of formula 10-8 (2.68g, 52% yield), Rf ═ 0.45 (30% ethyl acetate/petroleum ether).
Through the test:1H NMR(400MHz,Chloroform-d)δ7.07(s,1H),3.86(s,3H),3.81(s,3H),3.78(s,2H),3.75(s,3H),2.18(s,3H)；
13C NMR(101MHz,CDCl3)δ204.64,167.10,153.32,149.46,129.16,123.86,119.32,115.65,61.18,56.52,52.46,43.09,29.44；
HRMS(EI):m/z calcd for[M]+:330.0103,found:330.0107。
step h: preparing a compound of formula 10:
Figure BDA0001662678090000151
the compound of formula 10-8 (2.13g,6.43mmol) was dissolved in methanol (30ml), sodium borohydride (243 × 3mg,19.3mmol) was added in portions at 0 ℃, after completion of the addition, the reaction was carried out for 2 hours at 0 ℃ and then moved to room temperature for 2 hours, the reaction was terminated, acetone (3ml) was added to quench the reaction, the excess acetone was removed by concentration under reduced pressure, the residue was dissolved in ethyl acetate (50ml), washed once with saturated brine, dried, filtered, concentrated, and the residue was separated by column chromatography (5-15% ethyl acetate/petroleum ether) to give the compound of formula 10 (1.52g, yield 78%), Rf ═ 0.4 (30% ethyl acetate/petroleum ether).
Through the test: 1H NMR (500MHz, Chloroform-d) δ 7.13(s,1H),4.51(ddd, J ═ 11.5,6.2,2.8Hz,1H),3.94(s,3H),3.79(s,3H),3.19(dd, J ═ 16.5,2.8Hz,1H),2.73(ddd, J ═ 16.5,11.4,0.8Hz,1H),1.53(d, J ═ 6.3Hz, 3H);
13C NMR(126MHz,CDCl3)δ161.9,157.5,146.8,135.8,123.8,115.6,113.8,73.9,61.1,56.7,30.5,20.7；
MS(EI):300(M+,71),302(71),269(100),253(94)。
example 2: preparation of Compounds of formula 11
Step A: preparing a compound of formula 11-2:
Figure BDA0001662678090000152
dissolving the compound of formula 11-1 (7.20g,30.9mmol,1.0equiv.) in 60ml DMF, adding potassium carbonate (6.40g,46.3mmol,1.5equiv.) and benzyl bromide (4.0ml,34.0mmol,1.1equiv.), reacting at room temperature for 2 hours, terminating the reaction, adding 20ml distilled water to quench the reaction, extracting with ethyl acetate (30ml) three times, combining the organic phases, washing the organic phases with distilled water 3 times, washing with saturated sodium chloride solution 1 time, drying with anhydrous sodium sulfate, filtering, concentrating, and separating the residue with column chromatography (5% ethyl acetate/petroleum ether) to obtain the compound of formula 11-2 (8.97g, yield 90%), Rf ═ 0.57 (10% ethyl acetate/petroleum ether).
Through the test:1H NMR(400MHz,CDCl3)δ10.04(s,1H),7.43(d,J＝3.1Hz,1H),7.42–7.34(m,5H),7.24(d,J＝3.1Hz,1H),5.06(s,2H),3.81(s,3H)ppm；
13C NMR(100MHz,CDCl3)δ188.9,156.5,152.5,135.3,131.2,128.9,128.9(2C),128.8(2C),126.6,118.8,110.0,78.1,56.0ppm；
MS(EI):320(M+)。
and B: preparing a compound of formula 11-3:
Figure BDA0001662678090000161
dissolving the compound of formula 11-2 (30.3g,94.3mmol,1.0equiv.) in 260ml of dichloromethane solution, slowly adding m-chloroperoxybenzoic acid (38.20g,122.6mmol,1.3equiv.), reacting at 50 ℃ for 15 hours after the completion of the addition, finishing the reaction, cooling the system temperature to room temperature, adding sodium bicarbonate solid (11.88g,141.4mmol,1.5equiv.), stirring for 30 minutes, filtering with diatomite, separating the filtrate, washing the separated organic phase twice with 30ml of saturated sodium thiosulfate solution, then washing once with 30ml of saturated sodium bicarbonate solution and 30ml of saturated sodium chloride solution, drying, filtering and concentrating; the resulting concentrate was directly dissolved in 80ml of THF solution, 20ml of 10% NaOH aqueous solution was added at 0 ℃, followed by reaction at room temperature for 15 minutes to terminate the reaction, the reaction solution was concentrated under reduced pressure to remove excess THF, 50ml of ethyl acetate was added to the residue, pH was adjusted to about 4, then liquid separation was performed, ethyl acetate (40ml) was extracted three times, the organic phases were combined, the organic phase was washed once with 50ml of distilled water, once with 50ml of saturated sodium bicarbonate solution, once with 50ml of saturated sodium chloride solution, dried, filtered, concentrated, and the residue was separated by column chromatography (8% ethyl acetate/petroleum ether) to obtain the compound of formula 11-3 (22.4g, yield 77%) having Rf of 0.39 (15% ethyl acetate/petroleum ether).
Through the test:1H NMR(400MHz,CDCl3)δ7.46–7.36(m,5H),6.65(d,J＝2.9Hz,1H),6.44(d,J＝2.9Hz,1H),5.55(br s,1H),4.99(s,2H),3.72(s,3H)ppm；
13C NMR(100MHz,CDCl3)δ157.1,150.6,137.4,136.5,128.9(2C),128.8,128.6(2C),116.3,109.9,101.3,76.1,55.7ppm；
MS(EI):308(M+,3),229(14),91(100)。
and C: preparing a compound of formula 11-4:
Figure BDA0001662678090000171
a compound of formula 11-3 (3.09g,9.99mmol,1.0equiv.), Pd (PhCN)2Cl2(268mg,0.7mmol,0.07equiv.), cuprous iodide (66.7mg,0.35mmol,0.035equiv.), and sodium iodide (2.24g,14.99mmol,1.5equiv.) A mixed solvent of toluene and diisopropylamine (48ml, 40ml of toluene, 8ml of diisopropylamine) was added under nitrogen protection, triisopropylsilylacetylene (3.36ml,14.99mmol,1.5equiv.) was finally added, after the addition, the reaction was terminated at 110 ℃ under nitrogen protection, the reaction system was cooled to room temperature, 15ml of saturated aqueous ammonium chloride solution was added to quench the reaction, the reaction solution was extracted three times with ethyl acetate (30ml), the organic phases were combined, the organic phase was washed three times with distilled water, washed once with saturated sodium chloride solution, dried, filtered, concentrated, and the residue was separated by column chromatography (2-5% ethyl acetate/petroleum ether) to obtain the compound of formula 11-4 (3.44g, yield 84%), rf 0.48 (15% ethyl acetate/petroleum ether).
Through the test:1H NMR(400MHz,Chloroform-d)δ7.46–7.30(m,5H),6.54(d,J＝3.0Hz,1H),6.46(d,J＝3.0Hz,1H),5.55(s,1H),5.21(s,2H),3.74(s,3H),1.13(d,J＝2.2Hz,21H)ppm；
13C NMR(101MHz,CDCl3)δ155.9,149.7,140.9,137.0,128.7(2C),128.6,128.4(2C),116.7,110.0,102.8,102.8,96.3,75.9,55.7,18.7(3C),11.4(6C)。
step D: preparing a compound of formula 11-5:
Figure BDA0001662678090000172
the compound of formula 11-4 (3.44g,8.38mmol,1.0equiv.) was dissolved in 60ml of tetrahydrofuran, and then tetrabutylammonium iodide solution (10.9ml,10.9mmol,1.3equiv.) was added dropwise at 0 ℃, after completion of the addition, the reaction system was reacted at room temperature for 10 hours to terminate the reaction, 60ml of ethyl acetate was added for extraction, the organic phases were combined, washed once with 30ml of 1N hydrochloric acid aqueous solution, 30ml of distilled water and 30ml of saturated sodium chloride aqueous solution, respectively, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated by column chromatography (2-5% ethyl acetate/petroleum ether) to obtain the compound of formula 11-5 (1.58 g), with a yield of 77% Rf ═ 0.37 (15% ethyl acetate/petroleum ether).
Through the test:1H NMR(400MHz,Chloroform-d)δ7.47–7.33(m,5H),6.56(d,J＝3.0Hz,1H),6.51(d,J＝3.0Hz,1H),5.57(s,1H),5.15(s,2H),3.74(s,3H),3.35(s,1H)ppm；
13C NMR(101MHz,CDCl3)δ156.1,149.7,141.4,136.8,128.8(2C),128.7,128.6(2C),115.4,109.7,103.3,82.1,79.8,76.3,55.6。
step E: preparing a compound of formula 11:
Figure BDA0001662678090000181
after 50ml of dried dichloromethane, triethylamine (1.26ml,9.07mmol,1.5equiv.), triisopropylchlorosilane (1.4ml,6.6mmol,1.1equiv.) and a compound of formula 11-5 (1.54g,6.05mmol,1.0equiv.) were added under nitrogen protection, the reaction was terminated by adding 15ml of saturated aqueous ammonium chloride solution under nitrogen protection, followed by liquid separation, washing of the organic phase with 20ml of saturated aqueous sodium chloride solution, drying over anhydrous sodium sulfate, filtration, concentration, and separation of the residue by column chromatography (petroleum ether) to obtain a compound of formula 11 (2.05g, 82% yield), Rf ═ 0.87 (15% ethyl acetate/petroleum ether).
Through the test:1H NMR(500MHz,Chloroform-d)δ7.58–7.31(m,5H),6.59(d,J＝2.9Hz,1H),6.53(d,J＝3.0Hz,1H),5.06(s,2H),3.76(s,3H),3.23(s,1H),1.36–1.26(m,3H),1.13(d,J＝7.4Hz,18H)ppm；
13C NMR(125MHz,CDCl3)δ155.4,150.2,145.9,137.6,128.4(2C),128.2(2C),127.8,117.5,109.1,109.1,80.9,80.4,75.2,55.6,18.0(3C),12.9(6C)。
example 3: preparation of the Compound of formula 7
Figure BDA0001662678090000182
Dissolving the compound of formula 10 (1.52g,5.05mmol,1.0equiv.) and the compound of formula 11 (2.70g,6.56mmol,1.3equiv.) in a mixed solvent of 40ml DMF and 8ml triethylamine, adding Ph (PPh3)4(577mg,0.5mmol,0.1equiv.) and CuI (95.3mg,0.5mmol,0.1equiv.), reacting at 95 ℃ for 10.5 hours under nitrogen protection after the completion of the addition, finishing the reaction, cooling the reaction system to room temperature, and reacting with 10ml saturated NH4The reaction was quenched with aqueous Cl solution, extracted three times with ethyl acetate (40ml), the organic phases were combined, washed twice with distilled water and saturated brine, respectively, dried, filtered, and concentrated to give the compound of formula 7(2.50g, yield 78%).
Through the test:1H NMR(500MHz,Chloroform-d)δ7.58–7.49(m,2H),7.32(q,J＝6.2Hz,3H),6.85(s,1H),6.66(d,J＝3.0Hz,1H),6.57(d,J＝2.9Hz,1H),5.14(s,2H),4.52(ddd,J＝11.6,6.2,2.8Hz,1H),3.84(s,3H),3.81(s,3H),3.80(s,3H),3.17(dd,J＝16.6,2.8Hz,1H),2.67(dd,J＝16.6,11.5Hz,1H),1.52(d,J＝6.3Hz,3H),1.33(q,J＝7.5Hz,3H),1.14(d,J＝7.5Hz,18H)ppm；
13C NMR(125MHz,CDCl3)δ162.2,156.7,155.6,150.2,150.2,145.5,137.8,134.6,128.2(2C),127.9(2C),127.7,122.9,117.9,114.8,114.2,109.2,108.6,93.8,88.4,75.2,74.0,61.4,56.4,55.6,29.9,20.8,18.0(3C),12.9(6C)；
MS(m/z):ESI[M+H]+calcd for 631.31,Found[M+H]+:631.22。
example 4: preparation of Compounds of formula 5
The method comprises the following steps: preparing a compound of formula 8:
Figure BDA0001662678090000191
dissolving the compound shown in the formula 7(2.50g,3.95mmol) in tetrahydrofuran (80ml), adding palladium/barium sulfate (500mg,0.2w/w, 5% Pd) under the protection of nitrogen, stirring uniformly, introducing hydrogen, reacting at 35 ℃ for 11 hours under the atmosphere of hydrogen to finish the reaction, filtering the reaction liquid by using kieselguhr, and concentrating the filtrate to obtain the compound shown in the formula 8, wherein the compound shown in the formula 8 is directly used for the next reaction without purification.
Step two: preparing a compound of formula 9:
Figure BDA0001662678090000192
directly dissolving the compound of the formula 8 prepared in the step (i) in a mixed solvent of methanol (60ml) and dichloromethane (60ml), adding benzyltrimethyl ammonium dichloroiodate (2.05g,5.9mmol) and calcium carbonate (3.9g,39mmol), reacting at 50 ℃ for 10 hours to finish the reaction, filtering reaction liquid by using kieselguhr, concentrating the filtrate, dissolving the concentrate by using ethyl acetate, washing the concentrate by using a saturated sodium thiosulfate solution and a saturated sodium chloride solution respectively, drying by using anhydrous sodium sulfate, filtering, concentrating, and separating residues by using column chromatography (10-25% ethyl acetate/petroleum ether) to obtain the compound of the formula 9 (2.12g, wherein the total yield of the two steps (i) and (ii) is 71%), and Rf is 0.50 (30% ethyl acetate/petroleum ether).
Through the test:1H NMR(500MHz,Chloroform-d)δ7.48–7.31(m,5H),6.68(s,1H),6.49(s,1H),5.07–4.95(m,2H),4.48-4.41(m,1H),3.85(s,3H),3.70(s,3H),3.61(s,3H),3.18–3.04(m,3H),2.93–2.78(m,2H),2.71–2.61(m,1H),1.50(d,J＝6.3Hz,3H),1.40–1.27(m,3H),1.15(dd,J＝7.5,0.8Hz,18H)；
13C NMR(126MHz,CDCl3)δ162.8,157.4,154.5,150.1,147.8,141.9,141.9,139.4,137.8,134.5,128.3(2C),127.8,127.5(2C),112.3,112.2,102.3,82.0,74.6,73.9,61.5,56.7,56.1,36.6,30.2,30.2,20.8,18.0(3C),13.0(6C)；
MS(m/z):ESI[M+H]+calcd for 761.24,Found[M+H]+:760.70。
step three: preparing a compound of formula 5:
Figure BDA0001662678090000201
placing the compound of formula 9 (10 × 200mg,2.76mmol) in 10 clean quartz tubes respectively, adding dry and oxygen-removed acetonitrile (10 × 10ml,20mg/ml) by bubbling under nitrogen protection, adding 2, 6-lutidine (10 × 300 μ l) into each quartz tube, shaking uniformly, placing the photoreaction tube under 300nm ultraviolet illumination for reaction for 5 hours, ending the reaction, combining and spin-drying the solvents to obtain a concentrate, dissolving the concentrate with ethyl acetate, washing with 1N hydrochloric acid, a saturated sodium thiosulfate solution and a saturated sodium chloride solution in sequence, drying with anhydrous sodium sulfate, filtering, concentrating, and separating the residue with column chromatography (5-15% ethyl acetate/petroleum ether) to obtain the compound of formula 5 (1.47 g), wherein the yield is 83% Rf ═ 0.55 (30% ethyl acetate/petroleum ether).
Through the test:1H NMR(400MHz,Chloroform-d)δ7.41–7.27(m,5H),6.53(d,J＝3.7Hz,1H),5.01(s,2H),4.53(br s,1H),3.83(s,3H),3.65(s,3H),3.47(s,3H),3.19(dd,J＝16.5,2.8Hz,1H),3.10–2.99(m,2H),2.74-2.59(m,1H),1.98(td,J＝15.1,3.9Hz,1H),1.81(qd,J＝14.7,3.6Hz,1H),1.52(d,J＝6.1Hz,3H),1.42–1.31(m,3H),1.17(dd,J＝7.5,3.9Hz,18H)ppm；
13C NMR(125MHz,CDCl3)δ163.0,156.3,153.4,149.5,148.3,140.5,139.1,137.6,135.2,131.6,128.7(2C),128.3(2C),127.9,127.7,117.2,114.2,102.8,74.9,73.8,61.0,56.1,30.7,23.9,23.2,20.9,18.0(3C),13.0(6C)ppm；
HRMS(EI):m/z calcd for[M]+:632.3169,found:632.3167。
example 5: preparation of the Compound of formula 4
Figure BDA0001662678090000211
Adding a compound of formula 5 (633mg, 1.0mmol), a compound of formula 6 (221mg,1.2mmol) and cesium carbonate (293mg,0.9mmol) into dry and frozen deoxygenated N, N-dimethylformamide (45ml) under nitrogen protection, reacting the reaction system at 120 ℃ for 4 hours under nitrogen protection, cooling to room temperature, adding a 1N hydrochloric acid (10ml) solution, performing extraction quenching reaction, extracting with ethyl acetate for 3 times, combining organic phases, washing the organic phases with distilled water for 3 times, washing with saturated brine for 1 time, drying with anhydrous sodium sulfate, filtering, concentrating, and separating the residue by column chromatography (20-60% ethyl acetate/petroleum ether) to obtain a compound of formula 4 (253mg, yield of 41%), wherein Rf is 0.33 (40% ethyl acetate/petroleum ether).
Through the test:1H NMR(300MHz,Chloroform-d)δ10.41(s,1H),7.42(s,1H),7.31(br s,5H),6.55(s,1H),6.42(s,1H),5.06-4.96(m,2H),4.63–4.53(m,1H),3.96(s,3H),3.79(s,6H),3.74(s,3H),3.64(s,3H),3.32–3.01(m,3H),2.83–2.62(m,1H),2.08(tt,J＝28.4,14.5Hz,2H),1.56(d,J＝5.9Hz,3H)ppm；
13C NMR(125MHz,CDCl3)δ187.5,162.9,157.4,156.5,155.7,153.8,149.1,148.4,145.7,140.4,139.4,136.7,136.3,132.6,128.6(2C),128.4(3C),126.9,119.2,118.0,117.2,116.1,108.3,102.2,101.3,76.2,73.9,61.6,61.1,56.3(2C),30.8,23.9,23.1,20.8ppm；
HRMS(EI):m/z calcd for[M]+:640.2308,found:640.2314。
example 6: preparation of the Compound of formula 2
Figure BDA0001662678090000212
Dissolving a compound (301.8mg,0.471mmol) of a formula 4 in a mixed solvent of acetonitrile (15ml) and distilled water (3ml), adding sodium dihydrogen phosphate dihydrate (29.4mg,0.18mmol), hydrogen peroxide (106ul, 30% v/v,0.94mmol) and sodium chlorite (85mg,0.94mmol) at 0 ℃, stirring and reacting for 2 hours at 0 ℃ after the addition is finished, and then continuing to react for 4 hours at room temperature to obtain an oxidation product;
directly dissolving the obtained oxidation product in dry dichloromethane (10ml), adding N, N-dimethylformamide (20ul,0.26mmol) and oxalyl chloride (99ul,1.17mmol) at 0 ℃, reacting at room temperature for 1 hour, reacting for 1 hour, finishing the reaction, and removing the solvent to obtain an acyl chloride intermediate;
the resulting acid chloride intermediate was directly dissolved in hexafluoroisopropanol (2.5ml) under nitrogen protection, reacted at room temperature for 3 hours, the reaction was terminated, hexafluoroisopropanol was removed by concentration under reduced pressure, and the residue was separated by column chromatography (40% ethyl acetate/petroleum ether-50% ethyl acetate/petroleum ether + 10% ethyl acetate/dichloromethane) to give a compound of formula 2 (123mg, yield 41%) with Rf ═ 0.21 (50% ethyl acetate/petroleum ether).
Through the test:1H NMR(500MHz,Chloroform-d)δ7.71(d,J＝1.6Hz,1H),7.55–7.31(m,5H),6.83(s,1H),5.26–5.15(m,2H),4.67–4.56(m,1H),4.03(s,3H),4.02(s,3H),3.77(s,6H),3.68(s,3H),3.42–3.19(m,2H),3.13(ddd,J＝24.9,15.8,3.2Hz,1H),2.77(dd,J＝16.7,11.8Hz,1H),2.23–2.12(m,1H),2.10–1.98(m,1H),1.58(d,J＝6.2Hz,3H)ppm；
13C NMR(125MHz,CDCl3)δ174.8,162.7,157.0,154.9,154.6,150.7,150.5,148.0,146.9,140.2,140.0,138.6,137.0,133.0,128.5(4c),128.4,126.3,120.7,117.1,115.9,115.0,105.7,99.2,76.3,73.9,62.5,62.1,61.2,56.6,56.3,31.0,23.8,23.7,20.8；
HRMS(m/z):ESI[M+H]+calcd for 639.2225,Found[M+H]+:629.2223。
example 6: preparation of the Compound of formula 1, a Glycosyl ligand of calicheaxanthomycin A
Step 1): preparing a compound of formula 3:
Figure BDA0001662678090000221
under the protection of nitrogen, dissolving the compound of formula 2 (46mg,0.072mmol,1.0equiv.) in 10ml of dichloromethane, slowly adding boron trichloride (360 μ l,1.0M in dichloromethane, 0.36mmol,5.0equiv.) dropwise at-78 ℃, reacting at room temperature for 2 hours after the dropwise addition is finished, ending the reaction, cooling to 0 ℃, adding 2ml of distilled water to quench the reaction, separating liquid, washing an organic phase with a saturated sodium chloride solution for 1 time, drying with anhydrous sodium sulfate, filtering, concentrating, and separating a residue by column chromatography (1% dichloromethane/methanol) to obtain the compound of formula 3 (26.1mg, the yield is 69%), Rf 0.22 (4% dichloromethane/methanol).
Through the test:1H NMR(400MHz,Chloroform-d)δ13.09(s,1H),11.85(s,1H),7.50(s,1H),6.93(s,1H),5.56(s,1H),4.72(br s,1H),4.03(s,3H),3.98(s,3H),3.69(s,3H),3.37(s,1H),3.20(br s,2H),2.88–2.72(m,1H),2.22(br s,2H),1.59(d,J＝6.3Hz,3H)ppm；
13C NMR(125MHz,CDCl3)δ180.5,170.3,155.9,151.8,151.4,147.1,145.1,143.3,142.3,135.2,134.9,131.7,130.2,125.0,120.4,113.5,113.4,107.0,104.7,99.4.,75.8,61.4,56.6,56.4,29.7,23.2,22.8,20.9ppm；
HRMS(m/z):ESI[M+H]+calcd for 521.1442,Found[M+H]+:521.1434。
step 2): preparing a compound of formula 1, a calicheamicin a glycosyl ligand:
Figure BDA0001662678090000231
dissolving a compound (15.6mg,0.03mmol) of formula 3 in a mixed solution of acetonitrile and water (6ml, volume ratio is 5:1), adding iodobenzene bistrifluoroacetate (76.5mg,0.18mmol) at 0 ℃, reacting for 1 hour at 0 ℃, then reacting for 1 hour at room temperature after the addition is finished, finishing the reaction, adding sodium hydrosulfite to quench the reaction, decompressing and concentrating the reaction liquid to remove excessive acetonitrile, extracting the residue three times with ethyl acetate (5ml), combining organic phases, washing the organic phases for 1 time with saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, concentrating, separating the residue with a TLC plate (3% dichloromethane/methanol) to obtain a compound (2.8mg, 19%,) of formula 1, wherein Rf is 0.22 (4% dichloromethane/methanol).
Through the test:1H NMR(500MHz,DMSO-d6)δ13.02(s,1H),11.33(br s,1H),9.15(s,1H),8.55(s,1H),7.52(s,1H),7.21(s,1H),4.78(s,1H),4.00(s,3H),3.91(s,3H),3.44–3.36(m,1H),3.22(d,J＝17.1Hz,1H),2.72(dd,J＝16.9,11.6Hz,1H),2.40–2.32(m,1H),2.21–2.06(m,2H),1.49(d,J＝6.3Hz,3H).13C NMR(125MHz,CDCl3)δ185.6,175.7,161.3,157.1,155.7,152.0,149.6,146.2,143.2,141.8,137.5,135.9,134.7,131.0,124.2,118.4,117.7,111.7,109.3,105.3,80.8,61.7,61.1,45.3,34.2,28.4,25.78；
HRMS(m/z):ESI[M+H]+calcd for 507.1286,Found[M+H]+:507.1280。
the prepared carixanthomycin A glycosyl ligand is subjected to glycosylation reaction according to a conventional method to obtain the carixanthomycin A, and the glycosylation reaction belongs to a relatively mature technology, so that the detailed description of the invention is omitted.
In conclusion, the kallidamycin A glycosyl ligand is provided, kallidamycin A can be prepared by using the kallidamycin A glycosyl ligand, a reference basis is provided for the chemical synthesis of the kallidamycin A, and the preparation method has the advantages of simple operation, safety, no pollution, no special requirement on equipment, low production cost and the like, and has significant progress compared with the prior art; in addition, the carixanthomycin A glycosyl ligand provided by the invention has more modifiable sites, and intermediate compounds shown in formulas 2, 4, 5 and 7 and the like generated in the process of preparing the carixanthomycin A glycosyl ligand, and provides a new chemical synthesis direction for derivatives of the carixanthomycin A or other natural products with similar structures.
Finally, it should be pointed out here that: the above is only a part of the preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention, and the insubstantial modifications and adaptations of the present invention by those skilled in the art based on the above description are intended to be covered by the present invention.

Claims (5)

1. A preparation method of carixanthomycin A glycosyl ligand is characterized in that the carixanthomycin A glycosyl ligand has a chemical structure shown in a formula 1, and the preparation method comprises the following steps (2) or steps (1) to (2) in a synthetic route:
Figure FDA0002783903840000011
the compound of the formula 2 is selectively removed of carbonyl ortho methyl and benzyl in the compound of the formula 2 under the action of Lewis acid to obtain a compound of the formula 3 in the step (1); the compound in the formula (3) is selectively removed from the methyl group at the para position of the phenolic hydroxyl group in the compound in the formula (3) under the action of a dealkylation reagent to obtain the compound in the formula (1);
in the step (1), the Lewis acid is boron trifluoride, and a compound shown in a formula 2: the molar ratio of Lewis acid is 1: (3-8);
in the step (2), the dealkylation reagent is iodobenzene bistrifluoroacetate, and the compound shown in the formula 3: the molar ratio of dealkylating agent is 1: (4-8).
2. The method of claim 1, wherein the compound of formula 2 is prepared by the following steps: the compound of formula 4 is firstly subjected to oxidation reaction until aldehyde group in the compound of formula 4 is oxidized into carboxyl to obtain an oxidation product, and the oxidation product is subjected to intramolecular Friedel-crafts acylation reaction to obtain the compound of formula 2, wherein the chemical reaction formula is as follows:
Figure FDA0002783903840000012
3. the method of claim 2, wherein the compound of formula 4 is prepared by the following steps: the compound of formula 4 is obtained by aromatic nucleophilic substitution reaction of a compound of formula 5 and a compound of formula 6, and the chemical reaction formula is as follows:
Figure FDA0002783903840000021
4. the method according to claim 3, wherein the compound of formula 5 is prepared by the following steps (c) or (c) to (c):
Figure FDA0002783903840000022
5. the method of claim 4, wherein the compound of formula 7 is prepared by the following steps: the compound of formula 7 is obtained by the coupling reaction of a compound of formula 10 and a compound of formula 11 through sonogashira, and the chemical reaction formula is as follows:
Figure FDA0002783903840000023
CN201810469176.XA 2018-05-16 2018-05-16 California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof Expired - Fee Related CN108558899B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810469176.XA CN108558899B (en) 2018-05-16 2018-05-16 California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810469176.XA CN108558899B (en) 2018-05-16 2018-05-16 California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof

Publications (2)

Publication Number Publication Date
CN108558899A CN108558899A (en) 2018-09-21
CN108558899B true CN108558899B (en) 2021-02-26

Family

ID=63539187

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810469176.XA Expired - Fee Related CN108558899B (en) 2018-05-16 2018-05-16 California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof

Country Status (1)

Country Link
CN (1) CN108558899B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102679066B1 (en) * 2021-12-07 2024-06-27 한국해양과학기술원 Novel xanthone compounds with anticancer effect

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044383A (en) * 2011-10-17 2013-04-17 复旦大学 Method for preparing Penicillide racemate natural product
CN107235952A (en) * 2017-07-07 2017-10-10 华东师范大学 It is a kind of to help the synthetic method for pacifying moldin skeleton

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044383A (en) * 2011-10-17 2013-04-17 复旦大学 Method for preparing Penicillide racemate natural product
CN107235952A (en) * 2017-07-07 2017-10-10 华东师范大学 It is a kind of to help the synthetic method for pacifying moldin skeleton

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A photo-induced C–O bond formation methodology to construct tetrahydroxanthones;Zheming Xiao et al.;《ROYAL SOCIETY OF CHEMISTRY》;20141231;第50卷;5254-5257 *
Mining Soil Metagenomes to Better Understand the Evolution of Natural Product Structural Diversity: Pentangular Polyphenols as a Case Study;Hahk-Soo Kang et al.;《JOURNAL OF THE AMERICAN CHEMICAL SOCIETY》;20141218;第136卷;18111-18119 *

Also Published As

Publication number Publication date
CN108558899A (en) 2018-09-21

Similar Documents

Publication Publication Date Title
CN108558899B (en) California xanthene mycin A glycosyl ligand, intermediate and preparation method thereof
CN109369661B (en) Method for synthesizing chiral hydrogenated benzofuran compound by (3 + 2) cycloaddition dearomatization
CN111087278B (en) Siberian aromatic hydrocarbon compound and preparation method and application thereof
CN105924450B (en) Synthesis method of azafluorene spiro-aromatic hydrocarbon
CN108164493B (en) Aromatic polyketone compound and preparation method thereof
CN101993446A (en) Novel benzanthracene cyclic compounds and preparation method and use thereof
CN115260205B (en) Bipyrene-doped extended porphyrin, bipropylar metal complex thereof, preparation method and application thereof
JPS6247873B2 (en)
CN108250173B (en) Method for synthesizing benastatin J
WO2021233314A1 (en) METHODS FOR PREPARING β-D-(1,4)-MANNURONATE OLIGOSACCHARIDE AND INTERMEDIATE THEREOF
CN108276266B (en) Anthracycline compound and preparation method thereof
KR20240025659A (en) Method for producing planopropene and composition containing planopropene and impurities
CN108047186B (en) Method for synthesizing benastatin G
CN110386903B (en) Tetrazine-containing oligomeric phenylene acetylene compound and preparation method thereof
CN108101879B (en) Polycyclic lactone compound and preparation method thereof
CN113234113A (en) Method for efficiently constructing 1, 2-cis-2-nitro-glucoside and galactoside
CN113045580A (en) Synthetic method of aromatic polyketone compound ABX-C, BABX
CN111909100B (en) Method for preparing uracil and thymine derivatives
Furness et al. An efficient synthesis of 2-aryl and 2-alkenyl-3-alkoxy-cyclohexenones by a modified Stille reaction
CN109265352B (en) Preparation method of aryl cyclopropyl ether and derivatives thereof
Brimble et al. Synthesis of 3-azido-2, 3, 6-trideoxy-β-d-arabino-hexopyranosyl pyranonaphthoquinone analogues of medermycin
TWI833610B (en) Method and intermediates for preparing tricyclic compounds
CN110683940B (en) Method for converting dibenzo [ c, e ] [1,2] oxathiane-6-oxide compound
Skala Accessing Novel Graphene Nanoribbon Architectures through Double peri-Annulations
CN113372201A (en) Preparation method of biphenol compound and derivatives thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210226

CF01 Termination of patent right due to non-payment of annual fee